Reply  by Belch, Jill J.F. & Dormandy, John
a
t
n
a
t
t
t
b
e
o
s
c
n
T
t
i
t
r
b
E
t
(
i
d
b
A
a
W
t
o
t
e
r
t
T
m
J
I
U
D
J
V
S
L
R
1
d
T
a
a
T
JOURNAL OF VASCULAR SURGERY
May 20111454 Letters to the EditorI take issue with a point made by the authors twice within their
Discussion. Their assertion that clopidogrel reduces the failure rate
of prosthetic grafts to approximate that of venous grafts is un-
founded. This comparison simply cannot be made in their study in
a statistically valid fashion. Patients in the CASPAR trial were not
randomized to conduit; hence, it is highly likely that those patients
who received venous vs prosthetic grafts differed significantly in
key clinical and anatomic variables. The authors did not share the
relevant characteristics of the two conduit subgroups in the report.
Multiple high quality randomized trials have demonstrated the
clear superiority of venous over prosthetic grafts for LEB, even in
the above-knee position.3 The implication that clopidogrel treat-
ment might alter this established paradigm is not substantiated by
their trial, and I think highly speculative.
In comparing the data fromCASPARandbypass versus angioplasty
in severe ischemia of the leg (BASIL)4 to that from North American
studies suchasProjectorEx-VivoveingraftEngineeringviaTransfection
(PREVENT) III,5 I am struck by two persistent observations. Despite
the fact that two-thirdsof thepatients in theCASPARtrialpresentedwith
symptoms of critical ischemia, only 25% of the LEBs performed in this
study were at a tibial or pedal level. In BASIL roughly one-third of the
grafts performed were infrapopliteal, whereas in PREVENT III the
proportion was reversed (two-thirds were tibial/pedal). Therefore, I
question if the results from these trials are relevant to patients requiring
infrapopliteal bypass surgery, which appears more common in current
surgical practice on this side of the Atlantic, particularly in the endovas-
cular era. Finally, all of these trials continue to demonstrate inadequate
medical therapy in LEBpatients, specifically the lowutilization of statins,
whichwere associatedwith abeneficial effect in theCASPARtrial, aswell
as in PREVENTIII.6 Perhaps an intensive-dose statin trialmay still be of
relevance in the LEB population?
Michael S. Conte, MD
University of California San Francisco
San Francisco, Calif
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Reply
Thank you for the opportunity to comment on Dr Conte’s
letter, which asks some key questions. Dr Conte comments on the
randomization of patients a few days after the operation. The main
purpose of this study was to examine the benefits of treatment
without increasing the risk of bleeding. Although it could be
i
argued that as thrombus formation can occur intra-operatively
reatment should be started immediately, or indeed pre-surgery,
o one had previously explored the use of two potent antiplatelet
gents in these surgical patients. The decision was therefore taken
o initiate treatment a few days after surgery to ensure hemostasis at
he operation site. Patients were not excluded for reasons other
han protocol exclusion criteria.
Unfortunately, the point about the site of occlusion possibly
eing different between prosthetic and venous grafts cannot be
xplored, as the graft failure endpoint did not require details of the
cclusion site to be documented.
In this study, clopidogrel appeared to reduce prosthetic graft occlu-
ion to a rate found in patients undergoing venous grafting. Dr Conte is
orrect, however, that as randomization toprosthetic or venous graftwas
ot a function of this trial, these two sets of patients are not comparable.
hus, it ismore correct to state that although theocclusion rate appeared
o be reduced to the level seen in this trial’s venous graft group, further
nvestigation is required to confirm this finding.
Regarding the geographic inequality of distal grafts between the
hree trials mentioned in paragraph two, we recruited throughout Eu-
ope from one of the largest surgical trials of clopidogrel, and the distri-
ution was as reported. It may be that in PREVENT III (Project or
x-vivo Vein graft ENgineering via Transfection III) a selection bias for
hemoredistal graft patients probably reflected the fact that venousgrafts
studied in PREVENT III) aremuch preferred for the distal graft site. It
s thus possible that PREVENT III had a selection bias toward themore
istal grafts, rather thanCASPAR(Clopidogrel andAcetylsalicylic acid in
ypass Surgery forPeripheralARterial disease) andBASIL (Bypass versus
ngioplasty in Severe Ischaemia of the Leg) having a selection bias
gainst.
The writer’s observation regarding a statin trial is interesting.
e have tried to garner interest from pharmaceutical companies in
his hypothesis; however, it would necessitate bringing all patients
nto treatment and then providing more aggressive treatment to
he “active group.” The numbers required for such a study appar-
ntly seemed prohibitive to the companies. Interestingly, after our
ecent study of a gene therapy in clopidogrel, similar global statin
reatment rates were observed 5 years on from the CASPAR trial.1
his reflects the fact that peripheral artery disease remains the poor
an of cardiovascular disease: underdiagnosed and undertreated.
ill J. F. Belch, MD, FRCP
nstitute of Cardiovascular Research
niversity of Dundee, Ninewells Hospital
undee, Scotland, United Kingdom
ohn Dormandy, MD, FRCS
ice Chairman
t George’s Hospital
ondon, United Kingdom
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emperature measurements for dose-finding in steam
blation
We very recently demonstrated the safety and efficacy of steam
blation for varicose veins in sheep and humans in a pilot study.1
he effectiveness of endovenous thermal ablative treatments (us-
ng laser, radio frequency of steam) depends primarily on the
mount of energy delivered to the venous wall.2,3 Previously, it was
